Mason Hawkins's REGN Position Overview
Mason Hawkins (via Southeastern Asset Management Inc/Tn/) currently holds 144,607 shares of Regeneron Pharmaceuticals, Inc. (REGN) worth $81.31 M, representing 4.15% of the portfolio. First purchased in 2025-Q1, this short-term holding has been held for 3 quarters.
Based on 13F filings, Mason Hawkins has maintained this position in REGN for several quarters, showing initial confidence in the investment. Largest addition occurred in Q2 2025, adding 45,701 shares. Largest reduction occurred in Q3 2025, reducing 15,974 shares.
Analysis based on 13F filings available since 2013 Q2
Mason Hawkins's Regeneron Pharmaceuticals (REGN) Holding Value Over Time
Track share changes against reported price movement
Quarterly Regeneron Pharmaceuticals (REGN) Trades by Mason Hawkins
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2025 | +114,880 | New Buy | 114,880 | $634.23 |
| Q2 2025 | +45,701 | Add 39.78% | 160,581 | $525.00 |
| Q3 2025 | -15,974 | Reduce 9.95% | 144,607 | $562.27 |
Mason Hawkins's Regeneron Pharmaceuticals Investment FAQs
Mason Hawkins first purchased Regeneron Pharmaceuticals, Inc. (REGN) in Q1 2025, acquiring 114,880 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Mason Hawkins has held Regeneron Pharmaceuticals, Inc. (REGN) for 3 quarters since Q1 2025.
Mason Hawkins's largest addition to Regeneron Pharmaceuticals, Inc. (REGN) was in Q1 2025, adding 114,880 shares worth $72.86 M.
According to the latest 13F filing for Q3 2025, Mason Hawkins's firm, Southeastern Asset Management Inc/Tn/, owns 144,607 shares of Regeneron Pharmaceuticals, Inc. (REGN), valued at approximately $81.31 M.
As of the Q3 2025 filing, Regeneron Pharmaceuticals, Inc. (REGN) represents approximately 4.15% of Mason Hawkins's publicly disclosed stock portfolio, making it one of their key holdings.
Mason Hawkins's peak holding in Regeneron Pharmaceuticals, Inc. (REGN) was 160,581 shares, as reported at the end of Q2 2025.